HS-10353 vs KH607
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: GABA-A receptor · full Major Depressive Disorder pipeline
HS-10353
Developed by Hansoh Pharmaceutical Group
NCT05195203 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Endpoints of the trial:AE,SAE". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Reported efficacy
Endpoints of the trial:AE,SAE (Baseline to end of follow-up (a maximum of 20 days)): Phase 1 SAD (healthy, 2-55mg)/MAD (MDD patients, 15-65mg/day) trial: safe and well tolerated, no dose-adjusting AEs; exploratory HAM-D17 signal at 50mg dose: -4.7 vs placebo (95% CI -8.9 to -0.5), not significant at other doses
Result source: NCT05195203
KH607
Developed by Chengdu Kanghong Pharmaceutical
NCT07101120 · Phase 2 · completed
The study was randomized, quadruple-blind and placebo-controlled, with 126 participants, and used the clinical HAM-D17 score as its primary endpoint. The sponsors reported on 15 May 2026 that the study met its primary endpoint; they released no effect size, and the registry has no posted results, so the evidence is moderate.
Result as reported by the sponsors (15 May 2026 release); no effect size released and no results posted on ClinicalTrials.gov.
Next expected readout: December 2027 · NCT07741240 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Major Depressive Disorder
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | HS-10353 | KH607 |
|---|---|---|
| MADRS, change (acute) | —Not reported | —Trial running · NCT07741240 |
| CGI-S, change (acute) | —Not reported | —Trial running · NCT07741240 |
| MADRS response | —Not reported | —Trial running · NCT07741240 |
| MADRS remission | —Not reported | —Trial running · NCT07741240 |
| Relapse (% of patients) | —Not reported | —Trial running · NCT07741240 |
MADRS, change (acute)
- HS-10353
- —Not reported
- KH607
- —Trial running · NCT07741240
CGI-S, change (acute)
- HS-10353
- —Not reported
- KH607
- —Trial running · NCT07741240
MADRS response
- HS-10353
- —Not reported
- KH607
- —Trial running · NCT07741240
MADRS remission
- HS-10353
- —Not reported
- KH607
- —Trial running · NCT07741240
Relapse (% of patients)
- HS-10353
- —Not reported
- KH607
- —Trial running · NCT07741240
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
KH607: no structured comparison results are available for Major Depressive Disorder.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HS-10353's landscape · KH607's landscape